Scientific Clinical | Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology July 9, 2019
Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval July 1, 2019
Corporate | Nanobiotix appoints new chief medical officer as the company evolves after achievement of european market approval June 4, 2019
Scientific Clinical | Nanobiotix announces the launch of Curadigm : A new nanotechnology platform for healthcare May 28, 2019
Scientific Clinical | Nanobiotix announces first ever radioenhancer to receive european market approval April 4, 2019
Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer April 2, 2019
Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback March 26, 2019
Financial | Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank March 4, 2019
Financial | Nanobiotix Plans to Conduct Registered Public Offering in the United States January 16, 2019
Scientific Clinical | Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3 January 7, 2019
Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO October 19, 2018
Corporate | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank October 16, 2018
Scientific Clinical | Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences September 26, 2018
Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20, 2018
Financial | Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank July 26, 2018
Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 June 21, 2018
Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers May 3, 2018
Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway April 17, 2018
Scientific Clinical | The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement to run immunotherapeutic pre-clinical research in lung cancer combining NBTXR3 and Nivolumab April 10, 2018
Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting January 22, 2018
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers January 11, 2018
Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 13, 2017
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3 November 9, 2017
Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares October 31, 2017
Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering October 30, 2017
Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23, 2017
Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. September 28, 2017
Scientific Clinical | NANOBIOTIX: new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop June 15, 2017
Scientific Clinical | NANOBIOTIX: promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting June 5, 2017
Scientific Clinical | NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology May 18, 2017
Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares April 7, 2017
Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO April 4, 2017
Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma March 23, 2017
Scientific Clinical | Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017 March 7, 2017
Corporate | Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer February 7, 2017
Scientific Clinical | Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial December 14, 2016
Scientific Clinical | Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 November 28, 2016
Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer November 14, 2016
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia October 20, 2016
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations October 3, 2016
Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3 September 19, 2016
Corporate | Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe September 13, 2016
Scientific Clinical | Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer July 6, 2016
Scientific Clinical | Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31, 2016
Scientific Clinical | Nanobiotix starts a new research program in Immuno Oncology with its lead product NBTXR3 January 5, 2016
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer January 4, 2016
Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened November 13, 2015
Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 July 1, 2015
Scientific Clinical | Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 June 9, 2015
Scientific Clinical | Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan May 11, 2015
Corporate | Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization March 18, 2015
Financial | Nanobiotix secures financing from a major US investor, to address the US market November 25, 2014
Scientific Clinical | Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe October 16, 2014
Financial | Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers October 13, 2014
Scientific Clinical | PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific October 8, 2014
Scientific Clinical | Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO June 2, 2014
Scientific Clinical | Nanobiotix selected to present data from NBTXR3 clinical trial at ASCO April 1, 2014
Scientific Clinical | Nanobiotix sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 February 10, 2014
Corporate | Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar January 7, 2014
Scientific Clinical | Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar December 6, 2013
Corporate | Nanobiotix honored at the INVESTOR AWARDS 2013 in the “Young Talent” category November 7, 2013
Corporate | Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication July 3, 2013
Scientific Clinical | Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the NCI for development June 26, 2013
Scientific Clinical | Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3 June 13, 2013
Scientific Clinical | Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of- Concept in Phase I Trial of Soft Tissue Sarcoma June 3, 2013
Corporate | Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY April 3, 2013
Corporate | Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference March 19, 2013
Scientific Clinical | Phase I Independent Data Monitoring Committee confirms good safety of NBTXR3 in the first group of patients with advanced STS November 13, 2012
Corporate | Nanomed2020 intends to bring more nanomedicine products to European patients October 3, 2012
